Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06623513
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-27
Brief Title:
Efficacy and Safety of Parecoxib vs Indomethacin in Preventing Post-ERCP Pancreatitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-Center Prospective Randomized Controlled Exploratory Trial Comparing the Efficacy and Safety of Parecoxib vs Indomethacin in Preventing Post-ERCP Pancreatitis The PRECISE Trail
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRECISE
Brief Summary:
This study aims to evaluate the efficacy and safety of parecoxib versus indomethacin in preventing post-endoscopic retrograde cholangiopancreatography ERCP pancreatitis PEP It is a single-center prospective randomized controlled exploratory trial Participants will be randomly assigned to receive either parecoxib or indomethacin as a preventive treatment The primary endpoint is to compare the efficacy of the two drugs in reducing the incidence of PEP Secondary endpoints include the incidence of moderate to severe PEP and post-ERCP-related adverse events This study will systematically assess the efficacy and safety of both drugs providing preliminary data for future larger confirmatory trials
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None